Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 10:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 90 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Community Acquired Pneumonia Clear all
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Oxazolidinone to Treat Pneumonia

NCT00640926
View directory record Official record
Conditions
Community-Acquired Pneumonia (CAP)
Interventions
Radezolid
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
San Diego, California • Sylmar, California • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Jul 21, 2026, 10:24 PM EDT
Completed Phase 3 Interventional Results available

Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia

NCT00509106
View directory record Official record
Conditions
Bacterial Pneumonia
Interventions
Ceftaroline fosamil for Injection, Ceftriaxone, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
622 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Jul 21, 2026, 10:24 PM EDT
Not yet recruiting Phase 1 Interventional

OPT101 in Patients With Community Acquired Pneumonia (CAP) With Sepsis

NCT06669403
View directory record Official record
Conditions
Sepsis, Community Acquired Pneumonia (CAP)
Interventions
OPT101, Placebo
Drug · Other
Lead sponsor
Op-T LLC
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Jul 21, 2026, 10:24 PM EDT
Not yet recruiting Not applicable Interventional

Ketogenic Approach to Restore Muscle in Older Patients With Community-Acquired Pneumonia - KARMA-P Trial

NCT07308483
View directory record Official record
Conditions
Pneumonia
Interventions
Ketogenic feeding, Standard feeding
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
55 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Jul 21, 2026, 10:24 PM EDT
Not listed No phase listed Observational

Observational Study of Sepsis and Pneumonia to Develop Diagnostic Tests

NCT00258869
View directory record Official record
Conditions
Sepsis, Septicemia, Sepsis Syndrome, Shock, Septic, Community Acquired Pneumonia
Interventions
Not listed
Lead sponsor
National Center for Genome Resources
Other
Eligibility
6 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
3
States / cities
Detroit, Michigan • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 8, 2010 · Synced Jul 21, 2026, 10:24 PM EDT
Completed Phase 4 Interventional

Intravenous Azithromycin Plus Intravenous Ceftriaxone Followed by Oral Azithromycin With Intravenous Levofloxacin Followed by Oral Levofloxacin for the Treatment of Moderate to Severely Ill Hospitalized Patients With Community Acquired Pneumonia

NCT00035347
View directory record Official record
Conditions
Community-Acquired Pneumonia (CAP)
Interventions
IV azithromycin, ceftriaxone, oral azithromycin, IV levofloxacin, oral levofloxacin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
22
States / cities
Birmingham, Alabama • Long Beach, California • Sylmar, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Jul 21, 2026, 10:24 PM EDT
Active, not recruiting No phase listed Observational

Reducing Antibiotic Use by Implementation of Stewardship in Primary and Urgent Care

NCT07217002
View directory record Official record
Conditions
Community Acquired Pneumonia (CAP), Sinusitis, Strep Pharyngitis, Acute Otitis Media (AOM)
Interventions
Online Educational Modules, Prescribing Feedback Reports, Clinical Decision Support, Live, hybrid in-person and online educational sessions
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
6 Months to 12 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jul 21, 2026, 10:24 PM EDT
Completed Phase 3 Interventional

Use of Ceftaroline in Hospitalized Patients With Community Acquired Pneumonia

NCT01605864
View directory record Official record
Conditions
Community Acquired Bacterial Pneumonia
Interventions
Efficacy of ceftaroline
Drug
Lead sponsor
Albany Medical College
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Mar 23, 2014 · Synced Jul 21, 2026, 10:24 PM EDT
Terminated Phase 3 Interventional Results available

Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia

NCT05254990
View directory record Official record
Conditions
Infectious Pneumonia, Severe COVID-19
Interventions
Reparixin, Placebo
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
28
States / cities
Tucson, Arizona • Orange, California • Denver, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Jul 21, 2026, 10:24 PM EDT
Completed Phase 4 Interventional

Avelox for Treatment of Elderly Patients With Community Acquired Pneumonia

NCT00665327
View directory record Official record
Conditions
Pneumonia
Interventions
Avelox (Moxifloxacin, BAY12-8039), Levofloxacin
Drug
Lead sponsor
Bayer
Industry
Eligibility
65 Years and older
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
76
States / cities
Mobile, Alabama • Tucson, Arizona • Brea, California + 64 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2014 · Synced Jul 21, 2026, 10:24 PM EDT
Completed Phase 2 Interventional Results available

A Study Of Intravenous Sulopenem And Oral PF-03709270 In Community Acquired Pneumonia That Requires Hospitalization

NCT00797108
View directory record Official record
Conditions
Pneumonia, Bacterial
Interventions
Sulopenem and PF-03709270, Ceftriaxone and amoxicillin/clavulanate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
12
States / cities
Chula Vista, California • Oceanside, California • Moline, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2016 · Synced Jul 21, 2026, 10:24 PM EDT
Active, not recruiting No phase listed Observational

A Study to Learn About How Well the Prevnar 20 Vaccine Works for Pneumonia in People Who Are 65 Years and Older

NCT06782282
View directory record Official record
Conditions
Community-Acquired Pneumonia (CAP)
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
65 Years and older
Enrollment
22,234,435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jul 21, 2026, 10:24 PM EDT
Terminated Phase 2 Interventional Results available

Ticagrelor in Severe Community Acquired Pneumonia

NCT01998399
View directory record Official record
Conditions
Community Acquired Pneumonia, Severe
Interventions
Ticagrelor, Placebo
Drug
Lead sponsor
Gordon Bernard
Other
Eligibility
50 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
26
States / cities
Tucson, Arizona • Colorado Springs, Colorado • Denver, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2017 · Synced Jul 21, 2026, 10:24 PM EDT
Completed Phase 4 Interventional Results available

Trial to Evaluate Beta-Lactam Antimicrobial Therapy of Community Acquired Pneumonia in Children

NCT02891915
View directory record Official record
Conditions
Pneumonia
Interventions
Amoxicillin, Amoxicillin-clavulanate, Cefdinir, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 71 Months
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
9
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Louisville, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Jul 21, 2026, 10:24 PM EDT
Active, not recruiting Phase 2 Interventional

Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial Pneumonia

NCT05776004
View directory record Official record
Conditions
Pneumonia, Bacterial
Interventions
CAL02, Placebo
Drug
Lead sponsor
Eagle Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
Fresno, California • Gainesville, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Jul 21, 2026, 10:24 PM EDT
Completed Phase 3 Interventional

Tifacogin for the Treatment of Patients With Severe Community-Acquired Pneumonia

NCT00084071
View directory record Official record
Conditions
Pneumonia
Interventions
Tifacogin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
2,136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
51
States / cities
Mobile, Alabama • Loma Linda, California • Los Angeles, California + 48 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Jul 21, 2026, 10:24 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A 2-Part First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of CMTX-101

NCT05629741
View directory record Official record
Conditions
Community-acquired Pneumonia, Bacterial Pneumonia
Interventions
CMTX-101, Placebo
Drug
Lead sponsor
Clarametyx Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
8
States / cities
Augusta, Georgia • Idaho Falls, Idaho • Louisville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2024 · Synced Jul 21, 2026, 10:24 PM EDT
Active, not recruiting Not applicable Interventional

Discharge Stewardship in Children's Hospitals

NCT05826873
View directory record Official record
Conditions
Pneumonia, Bacterial, Pneumonia Childhood, Urinary Tract Infections, Soft Tissue Infections, Skin Infections, Community-acquired Pneumonia
Interventions
Discharge antibiotic stewardship intervention
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
28 Days to 18 Years
Enrollment
1,131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
5
States / cities
St Louis, Missouri • Philadelphia, Pennsylvania • Salt Lake City, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Jul 21, 2026, 10:24 PM EDT
Completed Not applicable Interventional

Using Probability of Community-Acquired Pneumonia to Tailor Antimicrobials Among Inpatients

NCT05976581
View directory record Official record
Conditions
Pneumonia, Pneumonia, Viral, Pneumonia, Bacterial
Interventions
Electronic alert, Structured communication of test results
Behavioral
Lead sponsor
Jonathan Baghdadi
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jul 21, 2026, 10:24 PM EDT
Recruiting Phase 3 Interventional

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
View directory record Official record
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Jul 21, 2026, 10:24 PM EDT
Completed Phase 3 Interventional Results available

Extended Steroid in Use in Community Acquired Pneumonia (CAP)(e)

NCT01283009
View directory record Official record
Conditions
Community Acquired Respiratory Disease Syndrome
Interventions
Inactive Substance, Methylprednisolone
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
29
States / cities
Phoenix, Arizona • Loma Linda, California • Long Beach, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2020 · Synced Jul 21, 2026, 10:24 PM EDT
Completed No phase listed Observational

Epidemiologic Study Of The Distribution Of Vaccine-Type Streptococcus Pneumoniae Serotypes In Adults In The US With Community-Acquired Pneumonia

NCT01086397
View directory record Official record
Conditions
Pneumonia, Pneumococcal, Vaccines, Pneumococcal
Interventions
Urine sample collection
Procedure
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
782 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
14
States / cities
Mobile, Alabama • La Mesa, California • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Jul 21, 2026, 10:24 PM EDT
Completed Not applicable Interventional

Outcomes of Patients Not Responding to Antibiotics in the Community

NCT00245427
View directory record Official record
Conditions
Sinusitis, Bronchitis, Chronic, Pneumonia, Bacterial
Interventions
all macrolide antibiotics, all beta-lactam antibiotics
Drug
Lead sponsor
CPL Associates
Other
Eligibility
Up to 95 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Oct 30, 2007 · Synced Jul 21, 2026, 10:24 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Clinical Indicators of Radiographic Findings in Patients With Suspected Community-Acquired Pneumonia

NCT00118651
View directory record Official record
Conditions
Pneumonia
Interventions
Not listed
Lead sponsor
David Grant U.S. Air Force Medical Center
Federal
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Travis Air Force Base, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2020 · Synced Jul 21, 2026, 10:24 PM EDT